ArticlemBio2017
Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types.
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 44 citations in OpenAlex.
- Engineering precision oncology: Targeting tumors and immune cells with lentiviral vectors.Molecular therapy. Oncology · 2026Review
- Genetically Encoded SpyTag Enables Modular AAV Retargeting via SpyCatcher-Fused Ligands for Targeted Gene Delivery.ACS synthetic biology · 2026Article
- Octopus-inspired engineered bacteria with a plug-and-play surface display system achieves enhanced tumor-specific colonization and antitumor immunity.Military Medical Research · 2026Article
- Epigenetic regulation of pathogenicity in fungi.Current genetics · 2025Review
- Enhancement of lentiviral vectors gene delivery against VEGFR2 expressing cells by co-display of the binding and fusogenic moieties: a two molecules targeting approach.Virology journal · 2025Article
- A novel pseudotype derived of the canine distemper virus for adapter-mediated lentiviral transductionMolecular therapy. Methods & clinical development · 2025Article
- Article
- Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Controlled labelling of tracer antibodies for time-resolved fluorescence-based immunoassays.Scientific reports · 2024Article
- In vivo selection of synthetic nucleocapsids for tissue targeting.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Different Strategies Affect Enzyme Packaging into Bacterial Outer Membrane Vesicles.Bioengineering (Basel, Switzerland) · 2023Article
- Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future.Current pharmaceutical biotechnology · 2023Review
- A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles.Journal of nanobiotechnology · 2022Article
- Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer.Viruses · 2022Article
- Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Fiber manipulation and post-assembly nanobody conjugation for adenoviral vector retargeting through SpyTag-SpyCatcher protein ligation.Frontiers in molecular biosciences · 2022Article
- From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.Journal of inflammation research · 2022Review
- Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells.Journal for immunotherapy of cancer · 2021Article
- Article
- Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a simple strategy for the creation of lentiviral vectors specific to any desired target cells. SpyTag is inserted into an engineered Sindbis virus envelope protein and displayed on the lentivirus surface to create Sindbis virus-SpyTag pseudoparticles (Sind-SpyTag-pp). The SpyTag serves as the covalent anchoring site for a target-cell-specific cell-binding protein (CBP) that is fused to a truncated SpyCatcher (SpyCatcherΔ). Target-cell-specific lentiviruses are created by mixing the Sind-SpyTag-pp and CBP-SpyCatcherΔ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.